Welcome to the Podiatry Arena forums

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members, upload content, view attachments, receive a weekly email update of new discussions, access other special features. Registered users do not get displayed the advertisements in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

  1. Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
    Dismiss Notice
Dismiss Notice
Have you considered the Clinical Biomechanics Boot Camp Online, for taking it to the next level? See here for more.
Dismiss Notice
Have you liked us on Facebook to get our updates? Please do. Click here for our Facebook page.
Dismiss Notice
Do you get the weekly newsletter that Podiatry Arena sends out to update everybody? If not, click here to organise this.

FDA approves KERYDIN™ (tavaborole) for toenail onychomycosis

Discussion in 'General Issues and Discussion Forum' started by NewsBot, Jul 8, 2014.

  1. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1

    Members do not see these Ads. Sign Up.
    Press Release:
    FDA Approves Anacor Pharmaceuticals’ KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails
    July 08, 2014
     
  2. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Tavaborole (AN-2690) for the treatment of onychomycosis of the toenail in adults.
    Gupta AK, Daigle D.
    Expert Rev Anti Infect Ther. 2014 Jul;12(7):735-42
     
  3. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Tavaborole: first global approval.
    Markham A
    Drugs. 2014 Sep;74(13):1555-8. doi: 10.1007/s40265-014-0276-7.
     
  4. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Potential role of tavaborole for the treatment of onychomycosis.
    Gupta AK, Daigle D.
    Future Microbiol. 2014;9(11):1243-50. doi: 10.2217/fmb.14.76.
     
  5. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Tavaborole topical solution, 5% for the treatment of toenail onychomycosis
    L.T. Zane, J. Plattner, Chanda, S., D. Coronado, T. Mercahant, M.R.K. Alley, A.K. Gupta
    Drugs Today 2015, 51(10): 599
     
  6. Lab Guy

    Lab Guy Well-Known Member

    So, if you prescribe Tavaborole, it will cost the health insurance industry or the patient about $8,000 for a 48 week course of treatment with a small chance of a total cure and high chance of recurrence even if it does actually help. Seems like that amount of money can be used for something more important.

    Steven
     
  7. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Tavaborole - a treatment for onychomycosis of the toenails.
    Gupta AK, Versteeg SG
    Expert Rev Clin Pharmacol. 2016 Sep;9(9):1145-52. doi: 10.1080/17512433.2016.1206467
     
  8. Dieter Fellner

    Dieter Fellner Well-Known Member

    Yet another, and expensive topical for fungal nails. The drug companies already market several potent anti-fungal medications that perform well in the lab. Yet the basic problem remains - penetrating the dense nail plate and leaving a patient with a protracted, expensive treatment course. Would it not make sense to combine the topical (e.g. Lamisil spray) with nail trephination to provide for a faster, more effective solution?
     
  9. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Tavaborole 5% Solution: A Novel Topical Treatment for Toenail Onychomycosis.
    Gupta G, Foley KA, Gupta AK
    Skin Therapy Lett. 2015 Nov;20(6):6-9.
     
  10. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    This clinical trial was just registered:
    An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
     
  11. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Examining the Benefits of the Boron-Based Mechanism of Action and Physicochemical Properties of Tavaborole in the Treatment of Onychomycosis.
    Bryan Markinson, Mahmoud Ghannoum, Tate Winter, Anthony Rycerz, Fernando Rock, and Aditya K. Gupta
    Journal of the American Podiatric Medical Association: January 2018, Vol. 108, No. 1, pp. 12-19.
     
  12. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Tavaborole in Difficult-to-Treat Onychomycosis Cases: A Post-hoc Assessment of Phase III Subjects.
    Aly R, Gupta AK, Winter T, Zane LT, Vlahovic T.
    J Drugs Dermatol. 2017 Oct 1;16(10):1016-1021.
     
  13. NewsBot

    NewsBot The Admin that posts the news.

    Articles:
    1
    Tavaborole 5% Topical Solution for the Treatment of Toenail Onychomycosis in Pediatric Patients: Results from a Phase 4 Open-Label Study
    Rich P, Spellman M, Purohit V, Zang C, Crook TJ.
    J Drugs Dermatol. 2019 Feb 1;18(2):190-195.
     
Loading...

Share This Page